EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study



Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study



Digestive Diseases and Sciences 51(1): 89-98



Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo. A validated questionnaire assessed dyspeptic symptoms at baseline and at 3, 6, and 12 months. Endoscopies and biopsies were performed at baseline and at 3 and 12 months. There was an overall trend, although not statistically significant, for a benefit of H. pylori eradication. Of the patients in the antibiotics group, 16 of 46 (35%) had symptomatic improvement, versus 9 of 43 (21%) in the control group (P = 0.164). In a secondary analysis, it was found that of the patients without endoscopic gastric erosions, 15 of 34 (44%) in the antibiotics group and 5 of 33 (15%) of controls had symptomatic improvement (P = 0.015). Helicobacter pylori eradication did not prove to be clinically beneficial, although a tendency to symptomatic benefit was detected. Further studies are necessary to confirm the implications of endoscopic gastric erosions in these patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 011865621

Download citation: RISBibTeXText

PMID: 16416218

DOI: 10.1007/s10620-006-3090-6



Related references

Helicobacter pylori eradication in non-ulcer dyspepsia A randomized, double-blind, placebo-controlled study with a 12-month follow-up. Gastroenterology 118(4 Suppl 2 Part 1): AGA A468, April, 2000

Helicobacter pylori eradication for non-ulcer dyspepsia A prospective, double-blind, randomized, placebo controlled study. Gastroenterology 110(4 SUPPL ): A91, 1996

The effect of eradication of Helicobacter pylori on symptoms of non-ulcer dyspepsia A randomized double-blind placebo controlled trial. Gut 37(SUPPL 1): A56, 1995

Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. Bmj 318(7187): 833-837, 1999

Bismuth subsalicylate suppression of Helicobacter pylori in nonulcer dyspepsia: a double-blind placebo-controlled trial. Digestive Diseases and Sciences 38(9): 1674-1680, 1993

Long-term follow-up of patients with non-ulcer dyspepsia after Helicobacter pylori eradication A randomized double-blind placebo-controlled trial. Gastroenterology 114(4 PART 2): A305, April 15, 1998

No increase of reflux symptoms or esophagitis in patients with non-ulcer dyspepsia 12 months after Helicobacter pylori eradication A randomized double-blind placebo-controlled trial. Gastroenterology 114(4 PART 2): A306, April 15, 1998

Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection: A prospective, randomized, double blind, and placebo-controlled study. Phytomedicine 15(6-7): 391-399, 2008

Failure of a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of H. pylori Eradication in H. pylori-Infected Patients with Functional Dyspepsia. Gut and Liver 5(4): 468-471, 2011

H pylori eradication for functional dyspepsia A long-term, randomized, prospective, double-blind, placebo-controlled study. Gut 43(SUPPL 2): A81, Sept, 1998

Eradication of Helicobacter pylori in functional dyspepsia: Randomised double blind placebo controlled trial with 12 months' follow up. BMJ 318(7187): 833-837, March 27, 1999

Failure of Helicobacter pylori eradication to influence site-specific relapse in high risk NSAID users Results of a large six month double blind randomised controlled clinical trial. Gastroenterology 114(4 PART 2): A145, April 15, 1998

Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Alimentary Pharmacology & Therapeutics 14(3): 317-324, 2000

Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 2: response of facets of clinical idiopathic parkinsonism to Helicobacter pylori eradication. A randomized, double-blind, placebo-controlled efficacy study. Helicobacter 10(4): 276-287, 2005

Clinical trials in nonulcer dyspepsia (NUD): a cautionary note. A closer look at "a double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia". Canadian Journal of Gastroenterology 11(2): 125-126, 1997